Mainz Biomed Statistics
Total Valuation
Mainz Biomed has a market cap or net worth of $6.82 million. The enterprise value is $8.00 million.
Important Dates
The next estimated earnings date is Monday, December 29, 2025, before market open.
| Earnings Date | Dec 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Mainz Biomed has 5.41 million shares outstanding. The number of shares has increased by 351.86% in one year.
| Current Share Class | 5.41M |
| Shares Outstanding | 5.41M |
| Shares Change (YoY) | +351.86% |
| Shares Change (QoQ) | +128.23% |
| Owned by Insiders (%) | 0.95% |
| Owned by Institutions (%) | 2.05% |
| Float | 4.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.90 |
| Forward PS | n/a |
| PB Ratio | 2.32 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 12.13 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.52, with a Debt / Equity ratio of 1.23.
| Current Ratio | 0.52 |
| Quick Ratio | 0.35 |
| Debt / Equity | 1.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.47 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -114.35% |
| Return on Invested Capital (ROIC) | -214.19% |
| Return on Capital Employed (ROCE) | -437.77% |
| Revenue Per Employee | $25,382 |
| Profits Per Employee | -$729,658 |
| Employee Count | 26 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 0.42 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.80% in the last 52 weeks. The beta is 0.26, so Mainz Biomed's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | -86.80% |
| 50-Day Moving Average | 1.53 |
| 200-Day Moving Average | 2.65 |
| Relative Strength Index (RSI) | 37.20 |
| Average Volume (20 Days) | 802,156 |
Short Selling Information
The latest short interest is 36,944, so 0.68% of the outstanding shares have been sold short.
| Short Interest | 36,944 |
| Short Previous Month | 170,931 |
| Short % of Shares Out | 0.68% |
| Short % of Float | 0.80% |
| Short Ratio (days to cover) | 0.08 |
Income Statement
In the last 12 months, Mainz Biomed had revenue of $659,935 and -$18.97 million in losses. Loss per share was -$8.39.
| Revenue | 659,935 |
| Gross Profit | 445,434 |
| Operating Income | -16.70M |
| Pretax Income | -18.97M |
| Net Income | -18.97M |
| EBITDA | -16.15M |
| EBIT | -16.70M |
| Loss Per Share | -$8.39 |
Full Income StatementBalance Sheet
The company has $1.91 million in cash and $3.09 million in debt, giving a net cash position of -$1.18 million or -$0.22 per share.
| Cash & Cash Equivalents | 1.91M |
| Total Debt | 3.09M |
| Net Cash | -1.18M |
| Net Cash Per Share | -$0.22 |
| Equity (Book Value) | 2.52M |
| Book Value Per Share | 0.62 |
| Working Capital | -2.90M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.46 million and capital expenditures $14,588, giving a free cash flow of -$15.45 million.
| Operating Cash Flow | -15.46M |
| Capital Expenditures | 14,588 |
| Free Cash Flow | -15.45M |
| FCF Per Share | -$2.85 |
Full Cash Flow StatementMargins
| Gross Margin | 67.50% |
| Operating Margin | -2,530.90% |
| Pretax Margin | -2,874.69% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Mainz Biomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -351.86% |
| Shareholder Yield | -351.86% |
| Earnings Yield | -278.16% |
| FCF Yield | -226.49% |
Analyst Forecast
The average price target for Mainz Biomed is $14.00, which is 1,011.11% higher than the current price. The consensus rating is "Buy".
| Price Target | $14.00 |
| Price Target Difference | 1,011.11% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 142.84% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 3, 2024. It was a reverse split with a ratio of 1:40.
| Last Split Date | Dec 3, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
Mainz Biomed has an Altman Z-Score of -19.22 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -19.22 |
| Piotroski F-Score | 4 |
